Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5983243 | 0.90 | CYP19A1 (0.56) | CYP19A1CYP2D6HRH1HTR2ASIGMAR1 | |
| SCHEMBL287568 | 0.71 | CYP11B1 (0.48) | CYP19A1CYP2D6SIGMAR1ALDH1A1 | |
| SCHEMBL5303970 | 0.70 | CYP19A1 (1.00) | CYP19A1CYP2D6 | |
| SCHEMBL5983077 | 0.67 | CYP19A1 (0.41) | CYP19A1CYP2D6HRH1HTR2ASIGMAR1 | |
| SCHEMBL3290730 | 0.65 | HRH1 (0.68) | CYP2D6HRH1HTR2ASIGMAR1ALDH1A1 | |
| SCHEMBL2732016 | 0.62 | HRH1 (0.65) | CYP2D6HRH1HTR2ASIGMAR1ALDH1A1 | |
| SCHEMBL844862 | 0.62 | HRH1 (0.65) | CYP2D6HRH1HTR2ASIGMAR1ALDH1A1 | |
| SCHEMBL27321444 | 0.62 | HRH1 (0.65) | CYP2D6HRH1HTR2ASIGMAR1ALDH1A1 | |
| SCHEMBL5738018 | 0.61 | HRH1 (0.56) | CYP19A1CYP2D6HRH1HTR2ASIGMAR1 | |
| SCHEMBL9073997 | 0.60 | HRH1 (0.71) | CYP19A1HRH1HTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
| EP-1232166-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | Pharmasset Limited (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001034618-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | PHARMASSET LIMITED (US) | 2001-05-17 | — | — | WO | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| EP-0552765-B1 | Benzimidazoles, pharmaceutical compositions containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1996-08-14 | — | — | EP | disclosed |
| US-5459147-A | Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma | DR. KARL THOMAE GMBH (DE) | 1995-10-17 | — | — | US | disclosed |
| EP-0560330-A2 | Substituted benzimidazolyl derivatives, therapeutic agents containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-09-15 | — | — | EP | disclosed |
| EP-0556789-A2 | Substituted biphenyl derivatives, therapeutic agents containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-08-25 | — | — | EP | disclosed |
| EP-0552765-A1 | Benzimidazoles, pharmaceutical compositions containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | CYP19A1 3440/4885CYP2D6 2064/4885HRH1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.